|
|
Volumn 73, Issue 3, 2006, Pages 231-233
|
|
Medical benefits from drugs
a,b
|
|
Author keywords
Drug evaluation; Drug reimbursement; French committee for assessment of medicinal products; French National Authority for Health
|
|
Indexed keywords
ADALIMUMAB;
BISPHOSPHONIC ACID DERIVATIVE;
ETANERCEPT;
HYALURONIC ACID;
INFLIXIMAB;
LEFLUNOMIDE;
NIMESULIDE;
PARATHYROID HORMONE[1-34];
ROFECOXIB;
STRONTIUM RANELATE;
ANKYLOSING SPONDYLITIS;
COMORBIDITY;
CONSENSUS;
DRUG APPROVAL;
DRUG CONTRAINDICATION;
DRUG EFFICACY;
DRUG INDICATION;
DRUG LABELING;
DRUG MARKETING;
DRUG SAFETY;
DRUG SURVEILLANCE PROGRAM;
DRUG WITHDRAWAL;
EDITORIAL;
EVALUATION;
HEALTH CARE ORGANIZATION;
HEALTH INSURANCE;
HUMAN;
INFORMED CONSENT;
LICENSING;
MEDICAL SOCIETY;
OFF LABEL DRUG USE;
OSTEOARTHRITIS;
OSTEOPOROSIS;
POSTMARKETING SURVEILLANCE;
PRESCRIPTION;
REIMBURSEMENT;
RHEUMATOID ARTHRITIS;
RISK BENEFIT ANALYSIS;
CLINICAL TRIALS;
DRUG APPROVAL;
DRUG TOXICITY;
FRANCE;
GOVERNMENT REGULATION;
HUMANS;
PUBLIC HEALTH;
RISK ASSESSMENT;
|
|
EID: 33646063179
PISSN: 1297319X
EISSN: None
Source Type: Journal
DOI: 10.1016/j.jbspin.2005.10.014 Document Type: Editorial |
|
Times cited : (1)
|
|
References (7)
|
